Molecular Imaging

Molecular imaging (also called nuclear medicine or nuclear imaging) can image the function of cells inside the body at the molecular level. This includes the imaging modalities of positron emission computed tomography (PET) and single photon emission computed tomography (SPECT) imaging. How does PET and SPECT imaging work? Small amounts of radioactive material (radiopharmaceuticals) injected into a patient. These can use sugars or chemical traits to bond to specific cells. The radioactive material is taken up by cells that consume the sugars. The radiation emitted from inside the body is detected by photon detectors outside the body. Computers take the data to assemble images of the radiation emissions. Nuclear images may appear fuzzy or ghostly rather than the sharper resolution from MRI and CT.  But, it provides metabolic information at a cellular level, showing if there are defects in the function of the heart, areas of very high metabolic activity associated with cancer cells, or areas of inflammation, data not available from other modalities. These noninvasive imaging exams are used to diagnose cancer, heart disease, Alzheimer’s and Parkinson’s disease, bone disorders and other disorders. 

3 industry partnerships, 1 clinical aim: Enriching the global supply chain of medical isotopes

Nuclear medicine operations may soon enjoy steadier flows of certain in-demand radioisotopes. If so, much credit will go to companies that had the strategic sense to collaborate with each other. 

Thumbnail

Tau tangles on PET scans may signal impending cognitive decline in asymptomatic individuals

New data highlight the significance of tau-positive imaging in the progression of Alzheimer’s disease. 

artificial intelligence in healthcare

'Promising' new PET agent for brain metastases put on FDA's Fast Track

Clinical trial results thus far have been promising, representing a significant step forward for the hundreds of thousands of patients affected by brain metastases. 

prostate cancer PSA

Earlier treatment with Pluvicto may be beneficial for patients with hormone-sensitive prostate cancer

The drug has shown a “clinically meaningful benefit” in these patients, suggesting its potential as an earlier treatment option than previously thought, Novartis reports. 

Thumbnail

Prostate cancer theranostic, said to match effectiveness of Pluvicto, heads to clinical trial

ART-101 is a prostate-specific membrane antigen-targeting small molecule that can pair with multiple isotopes, including actinium-225, lutetium-177 and terbium-161. 

Tariffs not enough to make Siemens Healthineers move production or raise prices—yet

The imaging manufacturer expects to spend between $227 million and $340 million on tariff mitigation efforts, leaders said Wednesday. 
 

PET imaging reveals long-term heart and lung damage from COVID-19

New data highlight the long-lasting effects of the coronavirus, revealing changes that are not detectable by standard medical assessments. 

PET method offers new insight into inflammation of the brain

Researchers are hopeful that their technique could improve the diagnosis of conditions associated with neural inflammation.